IV ferric carboxymaltose superior to ferrous fumarate for Improving anemia in children with IBD

The key findings of this study were as follows:

64 patients were randomly assigned, with 33 receiving IV iron and 31 receiving oral iron.

Patients in the IV group's 6MWD z-score had increased by 0.71 compared to -0.11 in the oral group a month after the commencement of iron therapy (P=0.01), however this difference was not statistically significant.

There were no discernible variations in 6MWD z-scores at the 3- and 6-month follow-ups.

At 1, 3, and 6 months after starting iron treatment, Hb z-scores steadily increased in both groups, with no difference in the rate of rise between groups (overall P=0.97).

In conclusion, no differences between oral and IV treatment were seen at 3 and 6 months following the start of the therapy. In both therapy groups, the rate of Hb augmentation over time was comparable.

Reference: 

Bevers, N., Van de Vijver, E., Aliu, A., Ardabili, A. R., Rosias, P., Stapelbroek, J., Maartens, I. A. B., van de Feen, C., Escher, J. C., Oudshoorn, A., Teklenburg, S., Velde, S. V., Winkens, B., Raijmakers, M., Vreugdenhil, A., Pierik, M. J., & van Rheenen, P. F. (2022). Ferric carboxymaltose versus ferrous fumarate in anemic children with inflammatory bowel disease: the POPEYE randomized controlled clinical trial. In The Journal of Pediatrics. Elsevier BV. https://doi.org/10.1016/j.jpeds.2022.12.016